<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04945226</url>
  </required_header>
  <id_info>
    <org_study_id>IVL3001-001</org_study_id>
    <nct_id>NCT04945226</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001</brief_title>
  <official_title>A Randomized, Open-Label, Exploratory, Pharmacokinetic, Sequential Single Ascending Dose Study of IVL3001 Versus Propecia (Finasteride) Tablets in Healthy Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inventage Lab., Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inventage Lab., Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Open-Label, Exploratory, Pharmacokinetic, Sequential Single Ascending dose&#xD;
      Study of IVL3001 Versus Propecia (Finasteride) Tablets in Healthy Adult Participants&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 30, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Cohort 1 / Cohort 2 (Group 1, Group 2) / Cohort 3</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast of IVL3001</measure>
    <time_frame>Pre-dose, 1008 hours</time_frame>
    <description>Area under the concentration-time curve from time zero to last</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of IVL3001</measure>
    <time_frame>Pre-dose, 1008 hours</time_frame>
    <description>Area under the concentration-time curve from time zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-1008h of IVL3001</measure>
    <time_frame>Pre-dose, 1008 hours</time_frame>
    <description>Area under the concentration-time curve from time zero to 1008 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of Propecia</measure>
    <time_frame>Pre-dose, 816 hours</time_frame>
    <description>Area under the concentration-time curve from time zero to last</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of Propecia</measure>
    <time_frame>Pre-dose, 816 hours</time_frame>
    <description>Area under the concentration-time curve from time zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-672h of Propecia</measure>
    <time_frame>Pre-dose, 672 hours</time_frame>
    <description>Area under the concentration-time curve from time zero to 672hours</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Androgenetic Alopecia</condition>
  <arm_group>
    <arm_group_label>Propecia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propecia Tablet, QD, PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVL3001 (A mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S.C, Single Dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVL3001 (B mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S.C, Single Dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVL3001 (C mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S.C, Single Dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finasteride 1mg Tablet</intervention_name>
    <description>Propecia Tablet 1mg</description>
    <arm_group_label>Propecia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVL3001</intervention_name>
    <description>Finasteride long acting injection</description>
    <arm_group_label>IVL3001 (A mg)</arm_group_label>
    <arm_group_label>IVL3001 (B mg)</arm_group_label>
    <arm_group_label>IVL3001 (C mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male, non-smoker or, if a moderate or occasional smoker (&lt; 10 cigarettes per&#xD;
             day or nicotine equivalent) must agree to abstain from smoking from 48 h before first&#xD;
             IP administration through to completion of the final EOS/ET visit, aged ≥ 18 to 55&#xD;
             years (inclusive at the time of informed consent)&#xD;
&#xD;
          -  In good general health, in the opinion of the Investigator, with no significant&#xD;
             medical history, and have no clinically significant abnormalities on complete physical&#xD;
             examination, 12-lead ECG, heart rate, and BP, both at Screening and before&#xD;
             administration of the initial dose of IP&#xD;
&#xD;
          -  Body mass index (BMI) between ≥ 18 kg/m2 and ≤ 32 kg/m2 and a minimum weight ≥ 50 kg&#xD;
             and ≤ 100 kg at Screening&#xD;
&#xD;
          -  Clinical laboratory values within normal limits, with normal range as specified by the&#xD;
             testing laboratory, unless deemed not clinically significant by the Investigator or&#xD;
             delegate&#xD;
&#xD;
          -  Ability and willingness to attend the necessary visits to the CRU and be domiciled&#xD;
             overnight&#xD;
&#xD;
          -  Willing and able to provide written informed consent after the nature of the study has&#xD;
             been explained and prior to the commencement of any protocol-specific study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior or ongoing medical conditions, medical history, physical examination findings,&#xD;
             or laboratory abnormalities that, in the Investigator's (or delegate's) opinion, could&#xD;
             adversely affect the safety of the participant&#xD;
&#xD;
          -  Presence or history of any clinically significant blood, kidney, endocrine, lung,&#xD;
             gastrointestinal tract, cardiovascular, liver, or neurological condition&#xD;
&#xD;
          -  Presence of any underlying physical or psychological (eg, depression) medical&#xD;
             condition that, in the opinion of the Investigator, would make it unlikely that the&#xD;
             participant will comply with the protocol or complete the study per protocol. Mild&#xD;
             depression and anxiety that has been resolved at least 6-12 months ago is accepted.&#xD;
&#xD;
          -  Presence of any medical condition that may affect oral drug absorption (eg,&#xD;
             gastrectomy, gall bladder removal, bariatric surgery, gastric bypass and sleeve, bowel&#xD;
             resection)&#xD;
&#xD;
          -  Hypersensitivity to finasteride or to any excipient of the IPs&#xD;
&#xD;
          -  Age adjusted PSA between 0 2.5 ng/mL for subjects ≤ 50 years of age and between 0-4&#xD;
             ng/mL for subjects &gt; 50 years of age at Screening, unless deemed not clinically&#xD;
             significant by the Investigator or delegate&#xD;
&#xD;
          -  History or known presence of any prostatic problem (infection, prostate cancer,&#xD;
             stricture disease, hypotonic bladder or other neurogenic disorder that might mimic&#xD;
             BPH)&#xD;
&#xD;
          -  Positive test for hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg), HIV&#xD;
             antigen or antibody at Screening&#xD;
&#xD;
          -  Positive toxicology screening panel (urine test including qualitative identification&#xD;
             of barbiturates, tetrahydrocannabinol [THC], amphetamines, benzodiazepines, opiates&#xD;
             and cocaine), or a positive alcohol breath (or urine), or cotinine test&#xD;
&#xD;
          -  History of alcohol or substance abuse or dependency, or history of recreational&#xD;
             intravenous (IV) drug use over the last 1 year (by self-declaration)&#xD;
&#xD;
          -  Regular alcohol consumption defined as &gt; 21 alcohol units per week (where 1 unit = 284&#xD;
             mL of beer, 25 mL of 40% spirit, or a 125 mL glass of wine) within 6 months of&#xD;
             Screening.&#xD;
&#xD;
          -  Use of any IP or investigational medical device within 3 months prior to Screening, or&#xD;
             five half-lives of the product (whichever is the longest), or participation in more&#xD;
             than 4 investigational drug studies within 1 year prior to Screening&#xD;
&#xD;
          -  Use of any drug known to significantly induce or inhibit drug absorption or metabolism&#xD;
             within 30 days prior to dosing&#xD;
&#xD;
          -  An employee, or relative of an employee, directly involved in the conduct of the study&#xD;
&#xD;
          -  Unwilling to refrain from strenuous exercise from 48 hours prior to admission to the&#xD;
             CRU at Day -1 and 48 hours prior to each follow-up&#xD;
&#xD;
          -  Presence of sexual dysfunction such as decreased libido, erectile dysfunction, or&#xD;
             ejaculation disorder&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt; 90 mL/min/1.73m2 at Screening&#xD;
&#xD;
          -  Any reason which, in the opinion of the PI, would prevent the subject from&#xD;
             participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 25, 2021</study_first_submitted>
  <study_first_submitted_qc>June 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Finasteride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

